DEPOMED,INC. (NASDAQ:DEPO) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operations and Financial Condition
On August 7, 2017, Depomed,Inc. issued a press release announcing its financial results for the three and six months ended June 30, 2017. The press release is attached hereto as Exhibit99.1 and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
99.1 Depomed,Inc. Press Release issued on August 7, 2017
DEPOMED INC ExhibitEX-99.1 2 a17-18883_1ex99d1.htm EX-99.1 Exhibit 99.1 Depomed Announces Second Quarter 2017 Financial Results – Updates Full-Year Financial Guidance – – Second Quarter Revenues of $100 million – – Increases Neurology Salesforce Effective September 1 – – Conference Call Scheduled for Today at 4:30 PM EDT; Dial In Information Below – NEWARK,…To view the full exhibit click here
About DEPOMED,INC. (NASDAQ:DEPO)
Depomed, Inc. is a specialty pharmaceutical company focused on pain and other central nervous system (CNS) conditions. The Company’s products include NUCYNTA ER (tapentadol extended release tablets), which is a product for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate; NUCYNTA (tapentadol), which is an immediate release version of tapentadol for the management of moderate to severe acute pain in adults; Gralise, which is a once-daily product for the management of postherpetic neuralgia; CAMBIA, which is a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Zipsor, which is a NSAID for the treatment of mild to moderate acute pain, and Lazanda nasal spray, which is used for the management of break through pain in cancer patients.
